Home / US / House Democrats ready to pick up GOP on drug price voting

House Democrats ready to pick up GOP on drug price voting







  Greg Walden "title =" Greg Walden "/> </source></source></source></source></picture>
            </div><figcaption>
<p>
                " It didn't have to be that way, "said Republican Republic of Walden. But they are just waiting to cut the TV ads. "Zach Gibson / Getty Images </p>
</figcaption></figure>
</p></div>
<p>  The House Democrats on Thursday will take their first big step toward lowering drug prices, but not before they make life difficult for Republicans <b><i> </i></b>  who helped them get there. </p>
<p>  The Chamber [19659006] will vote <b><i> </i></b>  on three biparticulate drug price calculations that the democratic leaders combine with a series of proposals aimed at reversing Trump's administration efforts to undermine Obamacare, which is likely to force most Republicans to lower the package and go on record as conflicting efforts Mixing Obamacare with drug pricing would also effectively kill legislative chances in the GOP-controlled Senate. </p><div>
<script async src=

Story Continued Below

The tactic has upset Republicans who spent months negotiating laws breaking down pharmaceutical companies and with called to mumble from m 8th Democrats who are keen to show some of the bipartisanship on a top health priority.

"I'm not very happy at all," says Rep Buddy Carter (R-Ga.), Whose proposition restricts the ability of generic drug companies to block competitors included in the package. "They know we won't be able to support this, and for them to say that, I just think it's poor politics."

House Democrats are defending the operation as a budgetary need. Trio of drug price bills would collectively save about $ 4 billion over a decade, making them valuable offsets for the Obamacare bills that require major federal spending to shore up health insurance markets and reverse cuts imposed by the administration.

None of the drug pricing measures is expected to dramatically reduce the cost of drugs. But they should restrict anti-competitive behavior from pharmaceutical companies and raise a question that polls show reasoning with voters of all political bands.

The Committee on Energy and Trade Committees, which unanimously supported the presentation of the bills on the floor last month, tried to fail to convince democratic leaders to hold occasional votes on drug price measures during a House Rules meeting on Tuesday night – and accused them of sacrifice good legislation to gain points on political points.

"It didn't have to be like this," said Principal Greg Walden (R-Ore.), The committee's member. "But they're just waiting to cut the TV ads."

The difficult feelings could seep into other common health-political priorities such as protecting patients from "surprise" medical bills and a number of important health-care policy extensions. 19659005] "For Republicans they say okay we did this once, but we have to trust you again," says Rodney Whitlock, a health consultant and former GOP congressman. "This is the first time – if there is a second time it will not be a third."

The inclusion of the Obamacare provisions makes everything else but certain that the Senate will ignore the combined package, which means that drug pricing measures in the limbo.

House Democratic leaders tentatively plan to revive these bills later this year and roll them into a wider must-pass legislation, a person familiar with the thinking said. However, it can be risky and delay action for up to half a year.

"Generally speaking, in a stronger ne gotiating position with the Senate when they do bipartisan work," Whitlock said. "It really says they won't be."

Democratic leaders completed the political benefits of designing a single healthcare package that considered these risks, according to people familiar with the strategy, especially on a problem that the party has made central to its platform before the 2020 elections.

The Democrats have already found a handful of Republicans who are willing to pay the Trump administration in health care. Four moderate Republicans last week broke the position of legislation that reverses Trump guidance encouraging states to avoid important Obamacare patient protection.

But the Democrats also worried that the GOP would arrest a bipartisan drug price vote as evidence President Donald Trump is following through on his promises to reduce drug costs. It can cost the Democrats leverage in negotiations on major priorities such as giving Medicare the opportunity to negotiate directly with pharmaceutical companies.

And the tactics put the Senate in place, which makes Republican leaders seem to impede the progress of drug prices if they do not take up the package.

"I would be very surprised if the ACA things survive the [House and Senate] conference unless Democrats decided they would rather have an agreement and live to fight another day," said drug industry lobbyist Michael Werner, who lobbied for some of the drug bills. "We have about one year until we are in full political season, and then all efforts are gone."

Some Democrats who had been pushing for a standalone drug pricing voiced abuses before Thursday's vote, arguing that it was important to claim early bipartisan profits after the party campaigned nationwide on slashing drug costs.

"Maybe I'm naive … I like people to get along," says Jeff-Drew, D-N.J., Swing Chief Jeff., Who stressed that he will still support the package. "It's nice to be able to go home and say that we passed legislation that was signed and now is law. That's the point. Just making bills to do bills is a bit difficult to go."

Household energy and trade health subcommittee chairman Anna Eshoo (D-Calif.) Had driven to separate the drug price and the ACA bills along with the ropes. Peter Welch who has spread much of the committee's work on drug pricing. Rope. David Cicilline (DR.I.) and Kurt Schrader (D-Ore.), Each leading sponsor of drug bills included in the package, were also among those who preferred a stand-alone vote.

"For now, it's okay. I think we're going to live to fight another day," said Schrader. "Our leadership still looks like playing in the sandbox right now, it's brand new to them. So I give them a little waste, they do a good job. "


Source link